Tagged with Interview

Pharma Amatsigroup, a Contract Development and Manufacturing Organization (CDMO), provides services throughout both preclinical and clinical phases. Leading over 200 highly qualified employees with a portfolio of over 300 clients, President Alain Sainsot shares Amatsigroup’s impressive recent growth which positions the company towards being a leading French player in its sector.…

Pharma Sobi is a leading integrated biopharmaceutical company dedicated to developing innovative therapies and services to improve the lives of rare disease patients and their families. Karel Fol, the country manager for Benelux shares the plans of the company for the Netherlands and Benelux, how Sobi is transforming its product portfolio,…

Pharma Providing an all-in-one venue for major corporate conference, seminar, or gala events, Disney Business Solutions at Disneyland Paris provides customized services to meet all clients’ needs. Director Nicolas Dupeux shares the unique amenities and services available that make any event at Disneyland Paris an experience like no other.   What…

Pharma Ferring Italy’s CEO discusses the affiliate’s successful management strategy, new products, new partnerships, and the potential of the Italian market. When we last interviewed you in 2009, you were focused on: (1) reinforcing the local organization’s structure, (2) successfully launching Firmagon, and (3) forging new partnerships in the IBD field.…

Pharma Five days before the January 25th revolution of 2011, Rameda changed ownership and CEO Amr Morsy set out to turn-around the mismanaged business. Five years later, revenues are up 4.5 times and the company is building a position as a regional leader in the Middle Eastern nutraceuticals market. In 2011,…

Pharma Francesco di Marco, General Manager for Amgen Italy, shares his view on the state of the Italian pharmaceutical sector, the turnaround the company has made in the country, and what he sees as the keys to unlocking Italy’s potential for innovation over the next few years. Having worked for Amgen…

Pharma Galderma Italy was a founding European affiliate for the company and has seen incredible growth in the past two decades. Managing Director  Bernat Albinyana discusses the affiliate’s performance, its business organization and commitment to R&D, as well as its grand ambitions for the next few years. In 1986, Italy was…

Pharma Tabuk Pharmaceuticals, the largest private Saudi pharmaceutical company with commercial operations in 25 countries in middle east and 5 European countries with a portfolio of more than 250 products, chose Egypt to consolidate its international presence in the Middle East and North Africa. The general manager for Egypt and Sudan…

Pharma Paul Korte, General Manager for Janssen in the Netherlands, highlights the strategic move and leadership position taken up by Janssen in the oncology field, and calls on Dutch healthcare stakeholders to adopt the positive and collaborative attitude that will ensure Dutch patients can still expect to access the most innovative…

Pharma Dr. Ermano Buratti, General Manager for Astellas Pharma in Italy, discusses the company’s evolution as it enters its second decade, the importance of partnering with the government on reimbursement, the current state and need for change in the country’s healthcare system, and his efforts to put Astellas in a position…

Pharma In an exclusive interview, the Vice President of Philips Research explains the key to continuous evolution, improving healthcare stakeholder relations, and fostering “Open Innovation.” You have been Vice President of Philips Research since 2007, a centenarian institution that stands as one of the largest private research organizations in the world.…

Pharma Healthcare is moving towards an increased level of personalization and active participation of the patient in the decision-making process. Roland van Esch, General Manager of Zimmer Biomet Netherlands, shares his perspective on how patient and hospital management will evolve in the future. In April 2014 Zimmer announced the acquisition of…